Humacyte Q3 net loss $26M; positive V005 trauma trial results, BLA filing planned this quarter

Humacyte, Inc.

2023-Q3 EPS reported -$0.83

Cash and equivalents $100M; funding from Oberland up to $160M, $40M received.
Net loss $26.0M Q3 2023 vs $25.3M Q3 2022; R&D expenses $18.6M.
V005 Phase 2/3 trial: 30-day patency 90.2%, amputation rate 9.8%, infection rate 2.0% (vs historic synthetic benchmarks).
BLA for HAV in vascular trauma planned for FDA filing in Q4 2023.
Ukraine humanitarian program: 30-day patency 95%, limb salvage and survival 100%, zero infections.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Humacyte, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal third quarter ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001818382-23-000160

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.